ERBB2 and breast carcinoma: Preliminary subgroup analysis by the number of HER2-targeted treatment lines for advanced breast cancer showed that ORR of study treatment as 1L and 2L HER2-targeted therapy was 85.7% (6/7) and 50.0% (4/8), respectively.